Zimmer Biomet Holdings, Inc. ZBH NYSE

Zimmer Biomet Holdings, Inc. (ZBH) has shown moderate revenue growth over the past 3 years, expanding from $6.9B to $8.2B (average +5.9%/yr). Net income reached $705M, reflecting exceptional earnings expansion at +102.9%/yr on average. The net profit margin is 8.6%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 61.6% (high), with a -9.3pp trend over the period. With a $19B market cap and MOAT composite score of 65/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (83/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 28-year history, the company was profitable in 26 of 28 years — an excellent long-term track record
• INCOME (45/100, Partial) — the company is profitable but margin is below 15%
• MOAT (65/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 63/100 with 2/7 criteria passed.